ICICI Securities has maintained its ‘Hold’ rating on Zydus Lifesciences Ltd. with a lower target price of Rs 900, citing a 4% downside. The company’s Q2 FY26 revenue was driven by recent acquisitions in consumer wellness and medtech divisions, but subdued margins and lower revenue of gRevlimid impacted Ebitda margin.
Mark Matthews, Head of Research Asia at Julius Baer, discusses the differences between the Indian and Chinese markets, and how both can continue to grow in parallel.
Indigo Paints Ltd.’s Q2 FY26 results have been reviewed by ICICI Securities, which has cut the target price despite maintaining an ‘Add’ rating. Find out why.
Lenskart, set to list on Monday, receives its first sell rating from Ambit due to valuation concerns and a capital-intensive business model.
Hindalco Industries Ltd reports a 21.2% rise in consolidated profit after tax at Rs 4,741 crore in Q2, driven by strong performance by the India business and disciplined cost management.
Indoco Remedies Ltd.’s Q2 FY26 earnings came above estimates, but Dolat Capital has downgraded its FY26E/FY27E Ebitda estimates, maintaining a ‘Sell’ rating with a revised target price.
The NSE Nifty 50 and BSE Sensex settled off day’s low as ICICI Bank Ltd. and Bajaj Finance Ltd. shares supported. The NSE Nifty Metal emerged as the top performing sector while the NSE Nifty It became the worst performing sector.
P&G Hygiene and Healthcare Ltd.’s Q2 performance was marked by weak gross margins, impacting profitability. Here’s what Motilal Oswal’s ‘Neutral’ stance means for investors and the company’s long-term growth prospects.
Nykaa’s Q2 results are out, with the company reporting a threefold increase in net profit and a 25.1% rise in revenue. What does this mean for investors and the future of the company?
Power Finance Corporation Ltd.’s net profit for the second quarter of FY26 saw a modest increase of 2.1%. The company has also declared a second interim dividend of Rs 3.65 per equity share.